dimecres, 23 de desembre del 2015

How TriVox is using online tracking to improve patient care

vector-blog-dec22-1x1Since we spoke with the founders of TriVox Health in 2014, their disease management program has taken off. The program began in Boston Children’s Hospital’s Division of Developmental Medicine as a way to more efficiently collect information on children’s ADHD symptoms from parents and teachers. It is now a user-friendly, web-based platform for tracking multiple conditions, incorporating medication confirmation, side effects reporting, disease symptom surveys and quality of life measures.

Vector-green logo

Vector sat down with founders Eric Fleegler, MD, MPH and Eugenia Chan, MD, MPH to learn about TriVox Health’s rapid growth over the past year, and what their plans are for the future.

How did TriVox Health branch out to other conditions beyond ADHD?

Chan: A lot of my colleagues started enrolling their kids with other disorders in order to get the quality of life measures. We quickly spread to other clinics within the hospital. Within the first year, we had enrolled 1,000 patients, including many without ADHD.

How many users do you currently have, and with what conditions?

Fleegler: TriVox Health is now being applied in nine clinics and across six conditions: ADHD, autism, anxiety, depression, epilepsy and asthma. To date, we’ve had 2.5 million questions answered from almost 5,000 patients and over 13,000 responders. We are working on expanding to other clinics within Surgery, Neonatology, Cardiology and Endocrinology. More conversations are always trickling up. We’re poised to go anywhere in the hospital.

Read the full post on VectorTriVox Health: improving care through shared online tracking

The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of MassDevice.com or its employees.

The post How TriVox is using online tracking to improve patient care appeared first on MassDevice.



from MassDevice http://ift.tt/1IpLewc

Cap comentari:

Publica un comentari a l'entrada